Peter Honig - Net Worth and Insider Trading

Peter Honig Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter Honig owns 5 companies in total, including Orexigen Therapeutics Inc (OREXQ) , Eiger BioPharmaceuticals Inc (EIGRQ) , and Sesen Bio Inc (SESN) among others .

Click here to see the complete history of Peter Honig’s form 4 insider trades.

Insider Ownership Summary of Peter Honig

Ticker	Comapny	Transaction Date	Type of Owner
OREXQ	Orexigen Therapeutics Inc	2017-07-14	director
EIGRQ	Eiger BioPharmaceuticals Inc	2014-03-02	director
SESN	Sesen Bio Inc	2021-07-20	director
		2021-12-03	director
		2021-07-20	director

Peter Honig Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Peter Honig Ownership Network

Ownership Network List of Peter Honig

No Data

Ownership Network Relation of Peter Honig

Peter Honig Owned Company Details

What does Orexigen Therapeutics Inc do?

Who are the key executives at Orexigen Therapeutics Inc?

Peter Honig is the director of Orexigen Therapeutics Inc. Other key executives at Orexigen Therapeutics Inc include 10 percent owner Baupost Group Gp, L.l.c. , 10 percent owner Baupost Group Llc/ma , and 10 percent owner Seth A Klarman .

Orexigen Therapeutics Inc (OREXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Orexigen Therapeutics Inc (OREXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Orexigen Therapeutics Inc (OREXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Orexigen Therapeutics Inc (OREXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Orexigen Therapeutics Inc Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Peter Honig is the director of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Peter Honig made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Sesen Bio Inc do?

Who are the key executives at Sesen Bio Inc?

Peter Honig is the director of Sesen Bio Inc. Other key executives at Sesen Bio Inc include 10 percent owner Modernatx, Inc. , director & President and CEO Steven Kelly , and Chief Financial Officer Richard Steven Morris .

Sesen Bio Inc (SESN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sesen Bio Inc (SESN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sesen Bio Inc (SESN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sesen Bio Inc (SESN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sesen Bio Inc Insider Transactions

No Available Data

What does Karyopharm Therapeutics Inc do?

Who are the key executives at Karyopharm Therapeutics Inc?

Peter Honig is the director of Karyopharm Therapeutics Inc. Other key executives at Karyopharm Therapeutics Inc include director & President and CEO Richard A. Paulson , EVP & CFO & Treasurer Michael Mason , and SVP Sales & Commercial Ops Sohanya Roshan Cheng .

Karyopharm Therapeutics Inc (KPTI) Insider Trades Summary

Over the past 18 months, Peter Honig made no insider transaction in Karyopharm Therapeutics Inc (KPTI). Other recent insider transactions involving Karyopharm Therapeutics Inc (KPTI) include a net sale of 165,682 shares made by Richard A. Paulson , a net sale of 55,845 shares made by Michael Mason , and a net sale of 41,559 shares made by Sohanya Roshan Cheng .

In summary, during the past 3 months, insiders sold 27,326 shares of Karyopharm Therapeutics Inc (KPTI) in total and bought 0 shares, with a net sale of 27,326 shares. During the past 18 months, 2,078,182 shares of Karyopharm Therapeutics Inc (KPTI) were sold and 41,140 shares were bought by its insiders, resulting in a net sale of 2,037,042 shares.

Karyopharm Therapeutics Inc (KPTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Karyopharm Therapeutics Inc Insider Transactions

No Available Data

What does CARISMA Therapeutics Inc do?

Who are the key executives at CARISMA Therapeutics Inc?

Peter Honig is the director of CARISMA Therapeutics Inc. Other key executives at CARISMA Therapeutics Inc include 10 percent owner Modernatx, Inc. , director & President and CEO Steven Kelly , and Chief Financial Officer Richard Steven Morris .

CARISMA Therapeutics Inc (CARM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CARISMA Therapeutics Inc (CARM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CARISMA Therapeutics Inc (CARM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CARISMA Therapeutics Inc (CARM)'s detailed insider trading history can be found in Insider Trading Tracker table.

CARISMA Therapeutics Inc Insider Transactions

No Available Data

Peter Honig Mailing Address

Above is the net worth, insider trading, and ownership report for Peter Honig. You might contact Peter Honig via mailing address: 3344 N. Torrey Pines Court, Suite 200, La Jolla Ca 92037.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.